Building on their existing collaboration, the companies have signed a new agreement to focus on lead optimization of drug candidates identified by Variational AI’s Enki™ generative AI platform and ...
VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0), a biopharmaceutical company advancing cancer therapies ...
The FIGHT-207 trial, led by Jordi Rodon, M.D., Ph.D., associate professor of Investigational Cancer Therapeutics, demonstrated promising early signs of clinical benefit and unveiled potential ...
ATR04-484 is a live biotherapeutic product targeting EGFR inhibitor-associated rashes in cancer patients, containing a modified Staphylococcus epidermidis strain. EGFR inhibitors, used in treating ...
Please provide your email address to receive an email when new articles are posted on . Three of four patients with neuroblastoma had stable disease through four or more treatment cycles. Phase 2 is ...
“[...] this study identifies gartisertib as a potent ATRi within patient-derived glioblastoma cell lines.” Glioblastoma cells can restrict the DNA-damaging ...
Rakovina Therapeutics Inc. has reported progress in its AI-driven KT-5000AI program, advancing the development of precision ATR (ataxia telangiectasia and Rad3-related) inhibitors designed to disrupt ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback